US FDA accepts Sun Pharma’s NDA for Deuruxolitinib
Deuruxolitinib is being evaluated for treatment of moderate to severe alopecia areata
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Alopecia Areata
US FDA asks Sun Pharma to stop trial on dermatological drug citing potential of blood clots
Sun Pharma acquired deuruxolitinib when it bought Concert Pharmaceuticals for $576 million earlier this year